PERSONALIS INC (PSNL)
Health Care · Cancer genomics and precision oncology diagnostics · NASDAQ
Personalis delivers ultra-sensitive cancer genomic sequencing and analysis for minimal residual disease detection, therapy monitoring, and precision oncology drug development.
What PERSONALIS INC does
Personalis develops and sells advanced cancer genomic testing services that use next-generation sequencing to detect residual or recurrent cancer, monitor therapy response, and guide treatment selection for physicians and oncology patients. The company provides testing to pharmaceutical companies for drug development, biomarker discovery, clinical trials, and personalized neoantigen therapy development. It also offers whole exome and whole genome sequencing services to diagnostics companies and provides WGS services under contract with the U.S. Department of Veterans Affairs Million Veteran Program.
Themes: ["Cancer genomics / oncology diagnostics","Minimal residual disease (MRD) monitoring","Precision oncology","Personalized cancer therapy","Biomarker discovery and clinical development","Immunotherapy monitoring","Clinical trial support","Population sequencing"]
Fundamentals
- Price$14.65 as of 2026-07-09 close
- Market cap$1.6B as of 2026-07-10
- 1-year return+104.6% as of 2026-07-09 close
- Net margin-148.1% as of 2026-07-10
- Gross margin+13.7% as of 2026-07-10
- ROE-43.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-24.7% as of 2026-07-10
- Revenue CAGR (3y)+2.3% SEC XBRL
- Beta2.29 as of 2026-07-10
Key risks (from latest filing)
["Revenue declined 25% in Q1 2026 due to lower pharma testing services, winding down of major Enterprise customer (Natera), and planned decline in VA MVP population sequencing revenue","Company is unprofitable with a net margin of -148.11% and negative revenue growth of -24.71% YoY, heavily dependent on reimbursement coverage decisions from Medicare and other payers","Competitive pressure and dependence on key partnerships including Tempus (collaboration through November 2029) and Moderna for clinical validation and market adoption"]
Competitors & peers
- Natera
- Foundation Medicine
- Guardant Health
- Invitae
- Tempus
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.